Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma

a potential rationale for immunotherapy

Toshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, Yui Hirata, Kan Kishibe, Yuki Komabayashi, Seigo Ueda, Miki Takahara, Takumi Kumai, Kei Ishibashi, Akemi Kosaka, Naoko Aoki, Kensuke Oikawa, Yuji Uno, Naoko Akiyama, Masatoshi Sado, Hidehiro Takei, Esteban Celis, Yasuaki Harabuchi, Hiroya Kobayashi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor therapeutic responses and prognosis. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays an important role in immune evasion of tumor cells through T-cell exhaustion. The aim of the present study was to examine the expression of PD-L1 and PD-1 molecules in NNKTL. We detected the expression of PD-L1 in biopsy samples from all of the NNKTL patients studied. PD-L1 was found on both malignant cells and tumor-infiltrating macrophages, while PD-1-positive mononuclear cells infiltrated the tumor tissues in 36% of patients. Most significantly, soluble PD-L1 (sPD-L1) was present in sera of NNKTL patients at higher levels as compared to healthy individuals and the levels of serum sPD-L1 in patients positively correlated with the expression of PD-L1 in lymphoma cells of tumor tissues. In addition, the high-sPD-L1 group of patients showed significantly worse prognosis than the low-sPD-L1 group. Furthermore, we confirmed that membrane and soluble PD-L1 was expressed on the surface and in the culture supernatant, respectively, of NNKTL cell lines. The expression of PD-L1 was observed in tumor tissues and sera from a murine xenograft model inoculated with an NNKTL cell line. Our results suggest that sPD-L1 could be a prognostic predictor for NNKTL and open up the possibility of immunotherapy of this lymphoma using PD-1/PD-L1 axis inhibitors.

Original languageEnglish (US)
Pages (from-to)877-890
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume66
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Nose
Immunotherapy
Ligands
Neoplasms
Lymphoma
Serum
Tumor Escape
Cell Line
Heterografts
Macrophages
T-Lymphocytes
Biopsy
Membranes

Keywords

  • Immunotherapy
  • Nasal NK/T-cell lymphoma
  • PD-1
  • PD-L1
  • Soluble form

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma : a potential rationale for immunotherapy. / Nagato, Toshihiro; Ohkuri, Takayuki; Ohara, Kenzo; Hirata, Yui; Kishibe, Kan; Komabayashi, Yuki; Ueda, Seigo; Takahara, Miki; Kumai, Takumi; Ishibashi, Kei; Kosaka, Akemi; Aoki, Naoko; Oikawa, Kensuke; Uno, Yuji; Akiyama, Naoko; Sado, Masatoshi; Takei, Hidehiro; Celis, Esteban; Harabuchi, Yasuaki; Kobayashi, Hiroya.

In: Cancer Immunology, Immunotherapy, Vol. 66, No. 7, 01.07.2017, p. 877-890.

Research output: Contribution to journalArticle

Nagato, T, Ohkuri, T, Ohara, K, Hirata, Y, Kishibe, K, Komabayashi, Y, Ueda, S, Takahara, M, Kumai, T, Ishibashi, K, Kosaka, A, Aoki, N, Oikawa, K, Uno, Y, Akiyama, N, Sado, M, Takei, H, Celis, E, Harabuchi, Y & Kobayashi, H 2017, 'Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy', Cancer Immunology, Immunotherapy, vol. 66, no. 7, pp. 877-890. https://doi.org/10.1007/s00262-017-1987-x
Nagato, Toshihiro ; Ohkuri, Takayuki ; Ohara, Kenzo ; Hirata, Yui ; Kishibe, Kan ; Komabayashi, Yuki ; Ueda, Seigo ; Takahara, Miki ; Kumai, Takumi ; Ishibashi, Kei ; Kosaka, Akemi ; Aoki, Naoko ; Oikawa, Kensuke ; Uno, Yuji ; Akiyama, Naoko ; Sado, Masatoshi ; Takei, Hidehiro ; Celis, Esteban ; Harabuchi, Yasuaki ; Kobayashi, Hiroya. / Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma : a potential rationale for immunotherapy. In: Cancer Immunology, Immunotherapy. 2017 ; Vol. 66, No. 7. pp. 877-890.
@article{aa6f0a81d2034c0baf775d837ec017be,
title = "Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy",
abstract = "Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor therapeutic responses and prognosis. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays an important role in immune evasion of tumor cells through T-cell exhaustion. The aim of the present study was to examine the expression of PD-L1 and PD-1 molecules in NNKTL. We detected the expression of PD-L1 in biopsy samples from all of the NNKTL patients studied. PD-L1 was found on both malignant cells and tumor-infiltrating macrophages, while PD-1-positive mononuclear cells infiltrated the tumor tissues in 36{\%} of patients. Most significantly, soluble PD-L1 (sPD-L1) was present in sera of NNKTL patients at higher levels as compared to healthy individuals and the levels of serum sPD-L1 in patients positively correlated with the expression of PD-L1 in lymphoma cells of tumor tissues. In addition, the high-sPD-L1 group of patients showed significantly worse prognosis than the low-sPD-L1 group. Furthermore, we confirmed that membrane and soluble PD-L1 was expressed on the surface and in the culture supernatant, respectively, of NNKTL cell lines. The expression of PD-L1 was observed in tumor tissues and sera from a murine xenograft model inoculated with an NNKTL cell line. Our results suggest that sPD-L1 could be a prognostic predictor for NNKTL and open up the possibility of immunotherapy of this lymphoma using PD-1/PD-L1 axis inhibitors.",
keywords = "Immunotherapy, Nasal NK/T-cell lymphoma, PD-1, PD-L1, Soluble form",
author = "Toshihiro Nagato and Takayuki Ohkuri and Kenzo Ohara and Yui Hirata and Kan Kishibe and Yuki Komabayashi and Seigo Ueda and Miki Takahara and Takumi Kumai and Kei Ishibashi and Akemi Kosaka and Naoko Aoki and Kensuke Oikawa and Yuji Uno and Naoko Akiyama and Masatoshi Sado and Hidehiro Takei and Esteban Celis and Yasuaki Harabuchi and Hiroya Kobayashi",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s00262-017-1987-x",
language = "English (US)",
volume = "66",
pages = "877--890",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",

}

TY - JOUR

T1 - Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma

T2 - a potential rationale for immunotherapy

AU - Nagato, Toshihiro

AU - Ohkuri, Takayuki

AU - Ohara, Kenzo

AU - Hirata, Yui

AU - Kishibe, Kan

AU - Komabayashi, Yuki

AU - Ueda, Seigo

AU - Takahara, Miki

AU - Kumai, Takumi

AU - Ishibashi, Kei

AU - Kosaka, Akemi

AU - Aoki, Naoko

AU - Oikawa, Kensuke

AU - Uno, Yuji

AU - Akiyama, Naoko

AU - Sado, Masatoshi

AU - Takei, Hidehiro

AU - Celis, Esteban

AU - Harabuchi, Yasuaki

AU - Kobayashi, Hiroya

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor therapeutic responses and prognosis. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays an important role in immune evasion of tumor cells through T-cell exhaustion. The aim of the present study was to examine the expression of PD-L1 and PD-1 molecules in NNKTL. We detected the expression of PD-L1 in biopsy samples from all of the NNKTL patients studied. PD-L1 was found on both malignant cells and tumor-infiltrating macrophages, while PD-1-positive mononuclear cells infiltrated the tumor tissues in 36% of patients. Most significantly, soluble PD-L1 (sPD-L1) was present in sera of NNKTL patients at higher levels as compared to healthy individuals and the levels of serum sPD-L1 in patients positively correlated with the expression of PD-L1 in lymphoma cells of tumor tissues. In addition, the high-sPD-L1 group of patients showed significantly worse prognosis than the low-sPD-L1 group. Furthermore, we confirmed that membrane and soluble PD-L1 was expressed on the surface and in the culture supernatant, respectively, of NNKTL cell lines. The expression of PD-L1 was observed in tumor tissues and sera from a murine xenograft model inoculated with an NNKTL cell line. Our results suggest that sPD-L1 could be a prognostic predictor for NNKTL and open up the possibility of immunotherapy of this lymphoma using PD-1/PD-L1 axis inhibitors.

AB - Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor therapeutic responses and prognosis. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays an important role in immune evasion of tumor cells through T-cell exhaustion. The aim of the present study was to examine the expression of PD-L1 and PD-1 molecules in NNKTL. We detected the expression of PD-L1 in biopsy samples from all of the NNKTL patients studied. PD-L1 was found on both malignant cells and tumor-infiltrating macrophages, while PD-1-positive mononuclear cells infiltrated the tumor tissues in 36% of patients. Most significantly, soluble PD-L1 (sPD-L1) was present in sera of NNKTL patients at higher levels as compared to healthy individuals and the levels of serum sPD-L1 in patients positively correlated with the expression of PD-L1 in lymphoma cells of tumor tissues. In addition, the high-sPD-L1 group of patients showed significantly worse prognosis than the low-sPD-L1 group. Furthermore, we confirmed that membrane and soluble PD-L1 was expressed on the surface and in the culture supernatant, respectively, of NNKTL cell lines. The expression of PD-L1 was observed in tumor tissues and sera from a murine xenograft model inoculated with an NNKTL cell line. Our results suggest that sPD-L1 could be a prognostic predictor for NNKTL and open up the possibility of immunotherapy of this lymphoma using PD-1/PD-L1 axis inhibitors.

KW - Immunotherapy

KW - Nasal NK/T-cell lymphoma

KW - PD-1

KW - PD-L1

KW - Soluble form

UR - http://www.scopus.com/inward/record.url?scp=85016094553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016094553&partnerID=8YFLogxK

U2 - 10.1007/s00262-017-1987-x

DO - 10.1007/s00262-017-1987-x

M3 - Article

VL - 66

SP - 877

EP - 890

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 7

ER -